Morning Overview on MSN
Universal nasal spray vaccine could block COVID, flu, and pneumonia
Stanford Medicine researchers have developed an experimental nasal spray vaccine that protected mice against SARS‑CoV‑2, ...
Vaccines have traditionally worked by teaching the immune system to recognize a specific virus or bacterium—in effect, ...
COVID-19 vaccination during the 2024-2025 respiratory virus season was associated with protection against hospitalization.
News-Medical.Net on MSN
Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation
By Hugo Francisco de Souza A novel nasal booster approach may help close the gap between systemic vaccination and infection-blocking mucosal immunity, offering fresh insight into next-generation COVID ...
Scientists at Stanford Medicine have unveiled a bold new kind of “universal” vaccine that could one day protect against everything from COVID-19 and the flu to bacterial pneumonia and even common ...
COVID-19 vaccination showed effectiveness in reducing hospitalizations and severe disease outcomes associated with the SARS-CoV-2 JN.1 lineage, according to a recent study published in JAMA Network ...
Add Yahoo as a preferred source to see more of our stories on Google. A nurse draws up doses of the Moderna COVID-19 for a vaccination clinic in St. Helena in 2021. Moderna is offering a new, low-dose ...
Researchers discovered another potential side effect that isn't getting nearly as much attention/ What is it and why is it important? Here's what you need to know. 🩺 SIGN UP for Parade’s health ...
Looking to get a COVID-19 vaccine booster for yourself or your child this fall? It may be a bit more complicated than just making an appointment. In August, the U.S. Food and Drug Administration ...
New FDA approval language for COVID-19 vaccines is sowing confusion about which conditions put people at greater risk for severe disease and who can avoid the inconvenience and cost of off-label ...
Clinical Trials Arena on MSN
Invivyd aligns with FDA advice on LIBERTY Phase III Covid-19 trial
The trial expects to enrol approximately 210 participants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results